Aligos Therapeutics (ALGS) Total Current Liabilities (2019 - 2026)

Aligos Therapeutics has reported Total Current Liabilities for 8 years, with the latest figure at $23.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 23.08% year-over-year to $23.3 million; the trailing twelve-month figure through Mar 2026 stood at $23.3 million (up 23.08% YoY), and the FY2025 full-year result was $21.2 million, down 2.32% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $23.3 million, up from $21.2 million in the prior quarter.
• The five-year high for Total Current Liabilities was $41.4 million in Q1 2022, with the low at $18.9 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $25.2 million across 5 years, with a median of $23.3 million in 2026.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 63.91% — and 2024, when it tumbled 32.76%.
• Aligos Therapeutics' Total Current Liabilities stood at $33.1 million in 2022, then fell by 27.84% to $23.9 million in 2023, then retreated by 9.07% to $21.7 million in 2024, then declined by 2.32% to $21.2 million in 2025, then increased by 9.84% to $23.3 million in 2026.
• The last three Total Current Liabilities figures came in at $23.3 million (Q1 2026), $21.2 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.